NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT02788773 2025-05-15
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03601455 2025-04-13
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03702179 2024-12-05
IMMUNOPRESERVE
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02819596 2024-11-04
CALYPSO
Queen Mary University of London
Phase 2 Completed
NCT03204812 2024-10-15
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00378482 2024-08-22
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Phase 2 Completed
NCT03557918 2024-07-03
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT03472274 2023-04-13
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT03430895 2021-12-01
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03081923 2021-05-14
APACHE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT03598816 2020-08-13
PIVOT-RCC
Washington University School of Medicine
Phase 2 Withdrawn
NCT03234153 2020-06-17
NITIMIB
Insel Gruppe AG, University Hospital Bern
Phase 2 Terminated
NCT03150836 2017-10-19
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
University of California, San Francisco
Phase 2 Withdrawn